Myriad Genetics (NASDAQ:MYGN) Issues Quarterly Earnings Results

05 May 2026, 19:22 by Amy Steele · The Cerbat Gem

Myriad Genetics (NASDAQ:MYGN – Get Free Report) issued its earnings results on Tuesday. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.03), FiscalAI reports. The company had revenue of $200.40 million during the quarter, compared to analysts’ expectations of $202.47 million. Myriad Genetics had a negative net margin of 44.38% and a negative return on equity of 6.35%.

Here are the key takeaways from Myriad Genetics’ conference call:

The company reaffirmed full‑year 2026 guidance with revenue of $860–$880M, adjusted gross margin of 68%–69%, and adjusted EBITDA of $37–$49M, after reporting Q1 revenue of $200.4M.
Alpha commercialization of Precise MRD (breast) is underway with ~12 onboarded sites, strong assay yield and turnaround times, and the company has accelerated select colorectal and renal rollouts toward broader commercialization into 2026–2027.
Management is investing $35M over several years and has added over 100 account executives focused on the cancer care continuum and prenatal channels, which should support launches but will take several quarters to reach full productivity and has driven higher near‑term OpEx.
Prenatal revenue declined ~15% YoY to $41.9M due to prior ordering disruptions and account losses; management expects stabilization and a return to growth in H2 2026 driven by the FirstGene launch but the segment remains a near‑term headwind.
GeneSight delivered strong performance with revenue up 24% YoY to $38.3M (7% volume growth), aided by improved reimbursement and a record ~39,000 ordering clinicians, supporting margin improvement.

Myriad Genetics Trading Up 1.8%

MYGN traded up $0.09 during mid-day trading on Tuesday, hitting $5.03. 1,398,967 shares of the stock were exchanged, compared to its average volume of 1,513,447. The firm’s fifty day moving average is $4.77 and its two-hundred day moving average is $5.92. Myriad Genetics has a 1-year low of $3.76 and a 1-year high of $8.59. The company has a current ratio of 2.49, a quick ratio of 2.26 and a debt-to-equity ratio of 0.33. The company has a market cap of $475.03 million, a PE ratio of -1.28 and a beta of 1.81.

Insider Activity

In other news, CEO Samraat S. Raha bought 40,000 shares of the firm’s stock in a transaction that occurred on Monday, March 9th. The shares were purchased at an average price of $5.00 per share, with a total value of $200,000.00. Following the purchase, the chief executive officer owned 493,104 shares in the company, valued at approximately $2,465,520. The trade was a 8.83% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director S. Louise Phanstiel bought 50,407 shares of the firm’s stock in a transaction that occurred on Thursday, February 26th. The shares were purchased at an average cost of $4.80 per share, for a total transaction of $241,953.60. Following the purchase, the director owned 233,951 shares in the company, valued at $1,122,964.80. This represents a 27.46% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders have purchased 144,507 shares of company stock worth $694,548. 1.90% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Myriad Genetics

Several hedge funds have recently bought and sold shares of the company. EverSource Wealth Advisors LLC raised its position in Myriad Genetics by 2,333.3% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 4,672 shares of the company’s stock valued at $25,000 after purchasing an additional 4,480 shares in the last quarter. Quarry LP raised its position in Myriad Genetics by 155.6% in the 4th quarter. Quarry LP now owns 4,365 shares of the company’s stock valued at $27,000 after purchasing an additional 2,657 shares in the last quarter. Royal Bank of Canada raised its position in Myriad Genetics by 129.6% in the 4th quarter. Royal Bank of Canada now owns 4,993 shares of the company’s stock valued at $31,000 after purchasing an additional 2,818 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in Myriad Genetics in the 2nd quarter valued at about $37,000. Finally, American Century Companies Inc. acquired a new stake in Myriad Genetics in the 2nd quarter valued at about $55,000. Institutional investors and hedge funds own 99.02% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. UBS Group dropped their target price on Myriad Genetics from $8.00 to $6.00 and set a “neutral” rating for the company in a report on Tuesday, February 24th. TD Cowen upgraded Myriad Genetics to a “hold” rating in a research report on Monday, April 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Myriad Genetics in a research note on Friday, March 27th. Wells Fargo & Company decreased their price target on Myriad Genetics from $6.50 to $6.00 and set an “equal weight” rating on the stock in a research note on Tuesday, February 24th. Finally, Zacks Research upgraded Myriad Genetics from a “strong sell” rating to a “hold” rating in a report on Thursday, February 26th. Four investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $8.94.

Check Out Our Latest Stock Analysis on Myriad Genetics

About Myriad Genetics

(Get Free Report)

Myriad Genetics (NASDAQ: MYGN) is a molecular diagnostics company that develops and commercializes genetic tests designed to assess an individual’s risk for various hereditary conditions and to guide personalized treatment decisions. The company’s core business centers on predictive medicine, with a focus on hereditary cancer risk assessment through its flagship BRACAnalysis® test for BRCA1 and BRCA2 gene mutations. In addition to oncology, Myriad offers tests in women’s health, neurology and pharmacogenomics to support more informed clinical decision-making.